The short version
- Why people research itSoft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
- What the evidence isThe parent protein TB-500 is a fragment of, and it reached phase 2 in humans — RegeneRx ran trials in dry eye disease and in venous stasis and pressure ulcers.
- What to watchA mole or lump that changes.
How Thymosin Beta-4 works
Full-length actin-sequestering peptide (TB-500 is its active fragment) — drives cell migration, angiogenesis, and tissue/cardiac repair.
This page is about the intact 43-residue protein, and the reason it needs its own page is that the fragment sold as TB-500 is missing the half of the molecule that does the anti-inflammatory work. Mature thymosin beta-4 is Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser, acetylated at the N-terminus.
The site map, which is the single most useful published fact about this protein. Its activities are assigned to distinct short sequences, not to the molecule as a whole Sosne 2010:
- Injectable
On the goal map: Thymic function & adaptive immunity (Immune resilience)
Research on Thymosin Beta-44 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
The parent protein TB-500 is a fragment of, and it reached phase 2 in humans — RegeneRx ran trials in dry eye disease and in venous stasis and pressure ulcers. The dry-eye program reported improvement in signs and symptoms; the wound program showed acceleration of healing in some cohorts. Neither reached approval and development stalled on funding rather than on a safety finding.
Correlative data
Used interchangeably with TB-500 in practice, though they are not the same molecule — the full 43-amino-acid protein versus the active fragment. Reported experience is indistinguishable, which is unsurprising given the fragment carries the actin-binding domain that does the work.
How the mechanism reads
An actin-sequestering protein present in most cells and elevated at wound sites. It promotes cell migration, angiogenesis and downregulation of inflammatory cytokines — a broader mechanism than the fragment alone.
MechanisticThe same pro-migratory, pro-angiogenic activity carries the same unanswerable long-term question as every repair peptide here.
Mechanistic
Sources
- Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal 2010 · PMID 20179146
- Wang W, et al. The Role of Tbeta4-POP-Ac-SDKP Axis in Organ Fibrosis. International Journal of Molecular Sciences 2022 · PMID 36362069
- Zoubek RE, Hannappel E. Influence of the N terminus and the actin-binding motif of thymosin beta4 on its interaction with G-actin. Annals of the New York Academy of Sciences 2007 · PMID 17495251
- Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration 2003 · PMID 12581423
- Sosne G, et al. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea 2015 · PMID 25826322
- Sosne G, et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clinical Ophthalmology 2015 · PMID 26056426
- Guarnera G, et al. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Annals of the New York Academy of Sciences 2007 · PMID 17495250
- Wang X, et al. Journal of Cellular and Molecular Medicine 2021 · PMID 34346165
Thymosin Beta-4 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Cancer history or an undiagnosed mass: actin-driven migration and angiogenesis help tumor growth.
- Proliferative eye disease: more angiogenic signaling worsens abnormal vessels.
- Pregnancy: angiogenesis and cell migration signals in placental tissue are untested.
- Very recent heart attack or stroke: effects on healing vessels are not human-tested.
What’s expected
- Possible sense of recovery, with its actin-sequestering action aiding cell migration and repair.
- Light-headedness or flushing after use.
- No firm human efficacy data.
Watch for
- A mole or lump that changes.
- Vision change or floaters while using Thymosin Beta-4.
- Chest pain or palpitations.
- Spreading redness.
Labs that tell you it’s working
- hs-CRP (C-Reactive Protein, High Sensitivity)
- Complete Blood Count (CBC) w/ Differential
- Fibrinogen Activity
- Comprehensive Metabolic Panel (CMP)
Thymosin beta-4 is the full-length actin-sequestering protein behind TB-500, with cardiac repair data in animals; evidence is animal and anecdotal. PMID 10469335 PMID 26056426
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Thymosin Beta-4 FAQ4 common questions
- Is Thymosin Beta-4 approved for human use?
- No. Thymosin Beta-4 is a research compound.
- What is Thymosin Beta-4 researched for?
- Soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
- Which labs show whether it's doing anything?
- hs-CRP; Complete Blood Count; Fibrinogen Activity; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Thymosin Beta-4: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




